Medical Device Cytotoxicity Analysis: In Vitro Testing Principles and Methods per ISO 10993-5

Medical device cytotoxicity analysis is the foundational step in biological safety evaluation, verifying that a device, its materials, and its leachable substances do not damage living mammalian cells in vitro. Performed in accordance with ISO 10993-5 within the ISO 10993 biocompatibility framework, this analysis is a regulatory expectation for market access worldwide, including US FDA 510(k) submissions, EU MDR conformity assessment, and registrations across Asia. This article explains the technical principles, sample requirements, test items, standard methods, acceptance criteria, and practical applications of cytotoxicity analysis for medical devices.

Technical Overview

Cytotoxicity analysis evaluates whether a medical device, its constituent materials, or substances released from them are capable of causing cell death, inhibiting cell growth, or inducing adverse morphological changes in cultured mammalian cells. It is specified in ISO 10993-5 (Biological evaluation of medical devices — Part 5: Tests for in vitro cytotoxicity) and forms a core component of the biological evaluation program defined by ISO 10993-1. Because it is rapid, sensitive, and cost-effective, cytotoxicity testing is almost always the first biological test performed on a new device or material.

The test detects potentially harmful leachables and degradation products, including residual monomers, plasticizers, stabilizers, colorants, adhesive residues, processing aids, cleaning agents, and sterilization residues such as ethylene oxide. These substances may migrate out of the device during clinical use and come into contact with patient tissue, making in vitro cell culture a powerful predictive screen for biological risk.

ISO 10993-5 defines three test categories based on the nature of contact between the sample and the cell culture: extract (elution) tests, direct contact tests, and indirect contact tests such as agar diffusion and filter diffusion. Both qualitative evaluation (microscopic grading of cell morphology and lysis) and quantitative evaluation (measurement of cell viability relative to untreated controls) are recognized. The standard establishes the widely cited acceptance threshold: if cell viability falls below 70% of the blank control, the sample is considered to have cytotoxic potential.

Complementary guidance is provided by ISO 10993-12 for sample preparation and reference materials, and comparable methodologies are described in ASTM F813 and ASTM F895. Regulators worldwide, including the US FDA, EU notified bodies, NMPA, and PMDA, expect cytotoxicity data generated in ISO/IEC 17025-accredited third-party laboratories or under equivalent quality systems as part of device technical documentation.

Testing Samples

Testing should ideally be performed on the final product in its final manufactured, sterilized, and packaged condition, since processing, sterilization, and secondary packaging can all influence the cytotoxic profile. Where the final device cannot be tested intact, representative materials and components are prepared under ISO 10993-12.

Finished Devices and As-Supplied Products

Patient-contacting portions of the finished device, such as catheter shafts, infusion tubing, wound contact layers, implant bodies, housings, and delivery system components, are extracted or placed into contact with cell cultures. Testing the sterilized, packaged product captures the contribution of sterilant residues and processing aids that would be missed in raw-material testing alone.

Raw Materials and Candidate Components

During design and development, cytotoxicity screening is performed on candidate polymers, resins, elastomers, metal coupons, ceramic specimens, coatings, curing agents, adhesives, inks, and colorants. Early screening supports material selection, supplier qualification, and comparative evaluation of alternative materials before tooling and production commitments are made.

Extract Preparation

For extract-based testing, samples are extracted under aseptic conditions in serum-supplemented culture medium (such as MEM or DMEM with fetal bovine serum), which simulates the in vivo environment and supports both polar and moderately non-polar leachables. Where justified, additional polar media (water, physiological saline) and non-polar media (such as cottonseed oil) may be used. Standard extraction conditions include 37°C for 24 hours, 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour, selected to exaggerate leaching without degrading the material unrealistically. Extraction ratios are standardized, commonly 3 cm²/mL or 6 cm²/mL of extraction medium depending on material thickness, or 0.1–0.2 g/mL for irregularly shaped porous solids, while hollow devices may be filled directly to their capacity.

Controls and Reference Materials

Each test includes a negative control, typically high-density polyethylene (HDPE) film, which is expected to produce no cytotoxic response; a positive control, such as natural rubber latex or certified cytotoxic reference materials like zinc diethyldithiocarbamate-containing polyurethane film, or a chemical positive control such as diluted detergent; and a blank control consisting of extraction medium processed identically without any test sample. Valid control performance is a prerequisite for a valid test.

Testing Items

Cytotoxicity analysis measures several complementary endpoints, selected according to the test method and the information required. The principal items evaluated include:

• Cell viability, quantified by metabolic assays such as MTT, XTT, WST-1, resazurin (Alamar Blue) reduction, or neutral red uptake (NRU)
• Cell proliferation and growth inhibition relative to untreated control cultures
• Morphological degeneration of cells, graded microscopically according to defined criteria
• Cell lysis, membrane damage, and loss of intracellular contents
• Zone of decolorization or cell lysis beneath and around solid specimens in diffusion methods
• Overall reactivity grade on the ISO 10993-5 scale from 0 (no reactivity) to 4 (severe reactivity)

For quantitative assays, viability is calculated as the percentage of the blank control, with 70% serving as the decision threshold. For qualitative assessment, ISO 10993-5 grading ranges from grade 0 (discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth) to grade 4 (nearly complete destruction of the cell layer). Grades 0 and 1 are generally regarded as non-cytotoxic, while higher grades trigger investigation into the responsible material, process, or extractable substance.

Testing Methods

ISO 10993-5 presents a range of test options, and the appropriate method is selected based on the physical form, density, and intended use of the device, as well as the nature of potential leachables. All methods use established mammalian cell lines, most commonly L929 mouse connective tissue fibroblasts, cultured under standard conditions of 37°C in a humidified atmosphere with 5% carbon dioxide.

Extract Method (Elution Test with MTT Viability Assay)

The extract method is the most widely used and versatile approach. The device extract is applied to confluent or near-confluent L929 monolayers in multi-well plates, typically for a 24-hour exposure period. Cell viability is then quantified, most commonly by the MTT assay, in which mitochondrial dehydrogenases in viable cells reduce the yellow tetrazolium salt to purple formazan crystals, which are solubilized and measured spectrophotometrically at approximately 570 nm. Viability is expressed as a percentage of the blank control, and serial dilutions of the extract can be tested to generate a dose-response profile. The method is suitable for virtually all device categories and offers objective, quantitative, and reproducible results.

Direct Contact Method

In the direct contact test, a sterile specimen is placed gently onto a sub-confluent cell monolayer and incubated for approximately 24 hours. Cytotoxic leachables diffuse directly into the culture medium, and any zone of cell distortion, lysis, or detachment beneath and around the specimen is assessed microscopically, often supplemented by a quantitative viability assay. The method is suited to low-density materials such as films, sheets, textiles, and wound dressings that rest on the cell layer. Because physical weight and impaired nutrient diffusion can mimic toxicity, interpretation must distinguish chemical cytotoxicity from mechanical artifacts.

Agar Diffusion Method (Agar Overlay)

In the agar diffusion test, cells are covered with a thin layer of nutrient agar containing a vital stain such as neutral red, which allows living cells to be visualized. The test specimen is placed on the agar surface, and cytotoxic substances diffuse through the agar layer to reach the cells during incubation, typically around 24 hours. The zone and degree of decolorization, cell lysis, and malformed cells are evaluated microscopically and graded. The method is appropriate for high-density solid materials and finished devices that would otherwise mechanically damage cells in a direct contact setup. Specimens must remain buoyant on the agar and must not absorb the agar or leach staining interference.

Filter Diffusion Method

In the filter diffusion test, cells are grown on a microporous membrane filter, the test specimen is placed on the filter surface, and toxic substances diffuse through to affect the underlying cells. This approach is useful for small solid specimens and materials that release diffusible cytotoxic components, and it is applied in specialized areas such as dental material evaluation.

Data Evaluation and Acceptance Criteria

A test is considered valid only when the negative control shows no cytotoxic response, the positive control demonstrates the expected cytotoxicity, and the blank and cell culture conditions meet the acceptance requirements of the standard. For quantitative evaluation, sample viability of 70% or greater relative to the blank indicates no cytotoxic potential, while results below 70% indicate a cytotoxic effect and typically prompt dilution studies, chemical characterization under ISO 10993-18, or material and process review to identify the causative agent.

Applications

Cytotoxicity analysis applies to every medical device category defined in ISO 10993-1 according to the nature of body contact and contact duration, ranging from limited contact of less than 24 hours to permanent implantation. Representative applications include:

• Surface-contacting devices: wound dressings, surgical gowns and drapes, gloves, adhesive tapes, examination electrodes, compression bandages, and external prosthetic interfaces
• External communicating devices: intravenous catheters, infusion sets and stopcocks, extension tubing, hemodialysis circuits, blood oxygenators, endoscopes and accessory tubing, and respiratory circuits
• Implantable devices: vascular stents and delivery systems, orthopedic implants, screws and plates, cardiac pacing leads, dental implants and restorative materials, absorbable scaffolds, and soft tissue implants

Beyond regulatory submission, cytotoxicity data supports material selection and design verification, qualification of alternative suppliers and materials, evaluation of sterilization method changes or residuals, extractables and leachables risk assessment, change control for reformulated resins or colorants, and root-cause investigation of field complaints or out-of-specification batches. Results are routinely included in FDA 510(k) and PMA submissions, EU MDR technical documentation and biological evaluation files, and registration dossiers with agencies such as NMPA, PMDA, and Health Canada, typically generated through accredited third-party laboratories operating under ISO/IEC 17025 or GLP quality systems.

FAQ

The following questions address the most common practical and regulatory concerns regarding cytotoxicity analysis of medical devices.

Why is cytotoxicity testing usually the first biocompatibility test performed?

The test is fast, sensitive, and relatively inexpensive compared with in vivo studies, allowing early identification of problematic materials or processing issues. A device that fails cytotoxicity screening is unlikely to succeed in subsequent biological tests, so resolving cytotoxicity findings first saves time and cost across the evaluation program.

Which cell line is used for the test?

The L929 mouse connective tissue fibroblast line is the reference cell culture recommended by ISO 10993-5 and is used by the majority of laboratories. Other established lines, such as BALB/c 3T3 fibroblasts or V79 cells, may be used when scientifically justified, and the cell line must be demonstrated to respond appropriately to the positive control in every test.

What is the pass criterion for the test?

For quantitative methods, cell viability of 70% or greater relative to the blank control indicates no cytotoxic potential. For qualitative methods, reactivity grades of 0 or 1 are generally acceptable, while grades of 2 or higher indicate a cytotoxic response requiring further investigation.

How long does cytotoxicity analysis take?

A standard MTT extract test typically requires approximately seven to fifteen working days from cell seeding to final report, including extraction, cell exposure, viability measurement, and documentation. Devices requiring multiple extraction conditions, multiple extraction media, or dilution series to characterize a borderline result may require additional time.

How much sample is required for testing?

Sample quantity is governed by the extraction ratio in ISO 10993-12. As a practical guide, laboratories commonly request 20 to 60 cm² of surface area or 2 to 6 g of material for a standard extraction test, plus additional units if polar and non-polar media or multiple extraction temperatures are specified. Accredited third-party laboratories provide sampling plans tailored to the device geometry.

Does passing a cytotoxicity test mean the device is fully biocompatible?

No. Cytotoxicity is only one endpoint within the biological evaluation plan defined by ISO 10993-1. Depending on the device category and contact duration, additional evaluations such as sensitization, irritation or intracutaneous reactivity, acute systemic toxicity, implantation, hemocompatibility, genotoxicity, and subacute or chronic toxicity may also be required.

What should be done if a sample fails the test?

A failure typically triggers dilution testing to characterize dose-response, chemical characterization of extractables under ISO 10993-18 to identify the causative substance, and review of materials, additives, cleaning processes, curing conditions, and sterilization residuals. Corrective actions may include material substitution, process modification, additional post-curing, or improved purification, followed by retesting to confirm resolution.